AP NEWS

Global Pancreatic and Bile Duct Cancer Drug Development Pipeline Review 2018 - ResearchAndMarkets.com

September 24, 2018

DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The ” Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 ” report has been added to ResearchAndMarkets.com’s offering.

This report Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin.

Signs and symptoms include upper abdominal pain, yellowing of the skin and the whites of the eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatments include surgery, chemotherapy and radiation therapy. There are 759 products in development for this indication.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile ducts, a series of tubes in the biliary tract that are essential for the secretion of bile, which plays an important role in digestion. Symptoms include discomfort in the abdomen, loss of appetite, fevers and weight loss. Treatment includes chemotherapy and radiation therapy. There are 133 products in development for this indication.

Molecular targets acted on by products in development for pancreatic and bile duct cancer include vascular endothelial growth factor receptors, programmed cell death protein 1 and signal transducer and activator of transcription 3.

Scope

Which companies are the most active within the pipeline for pancreatic and bile duct cancer? Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened within this field?

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Pancreatic and Bile Duct Cancer Report Coverage

2.2 Pancreatic Cancer - Overview

2.3 Bile Duct Cancer (Cholangiocarcinoma) - Overview

3 Therapeutics Development

3.1 Pancreatic Cancer

3.2 Bile Duct Cancer (Cholangiocarcinoma)

4 Therapeutics Assessment

4.1 Pancreatic Cancer

4.2 Bile Duct Cancer (Cholangiocarcinoma)

5 Companies Involved in Therapeutics Development

5.1 Pancreatic Cancer

5.2 Bile Duct Cancer (Cholangiocarcinoma)

6 Dormant Projects

6.1 Pancreatic Cancer

6.2 Bile Duct Cancer (Cholangiocarcinoma)

7 Discontinued Products

7.1 Pancreatic Cancer

7.2 Bile Duct Cancer (Cholangiocarcinoma)

8 Product Development Milestones

8.1 Pancreatic Cancer

8.2 Bile Duct Cancer (Cholangiocarcinoma)

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/vtx88w/global_pancreatic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005637/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Pancreatic Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: EDUCATION UNIVERSITY HEALTH ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/24/2018 10:46 AM/DISC: 09/24/2018 10:46 AM

http://www.businesswire.com/news/home/20180924005637/en

AP RADIO
Update hourly